BioAge Labs’ (BIOA) Buy Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of BioAge Labs (NASDAQ:BIOA) in a research note released on Monday morning,Benzinga reports. The firm currently has a $40.00 target price on the stock.

Other equities analysts have also issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, July 21st. Needham & Company LLC reduced their target price on BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Jefferies Financial Group set a $21.00 target price on BioAge Labs in a research report on Friday, July 31st. Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Finally, Roth Capital reiterated a “buy” rating and issued a $25.00 price target on shares of BioAge Labs in a report on Friday, July 31st. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $36.57.

BioAge Labs Stock Down 2.0%

Shares of BIOA stock opened at $10.98 on Monday. The firm has a 50 day moving average of $20.27 and a 200-day moving average of $19.30. The company has a market cap of $488.06 million, a price-to-earnings ratio of -4.57 and a beta of 0.93. BioAge Labs has a 52 week low of $4.25 and a 52 week high of $25.95.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.07. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. Analysts anticipate that BioAge Labs will post -2.68 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BIOA. Geode Capital Management LLC grew its holdings in shares of BioAge Labs by 60.8% during the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after buying an additional 171,426 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of BioAge Labs during the second quarter worth about $64,000. Marshall Wace LLP raised its holdings in shares of BioAge Labs by 324.7% in the 2nd quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock worth $937,000 after acquiring an additional 173,388 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in BioAge Labs by 85.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after acquiring an additional 5,976 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new position in BioAge Labs in the 2nd quarter valued at about $182,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.